Introduction {#S0001}
============

Glaucoma drainage implants lower intraocular pressure by draining aqueous through a long silicone tube to a plate implanted posterior to the limbus. The Ahmed Glaucoma Valve (New World Medical Inc., Rancho Cucamonga, CA) is a flow-restrictive glaucoma drainage device, which has a valve-like mechanism that reduces hypotony and associated complications in the early postoperative period.[@CIT0001] The utilization of glaucoma drainage implants, including the Ahmed Glaucoma Valve, has dramatically grown in recent years, increasing by 410% during the period from 1994 to 2012.[@CIT0002] Variables related to the plate have been found to influence clinical outcomes with glaucoma drainage implants,[@CIT0003] including surface area and plate material.[@CIT0004],[@CIT0005]

The M4 model of the Ahmed Glaucoma Valve has a plate made of porous, high-density polyethylene (Medpor; Porex, Atlanta, GA; subsequently Stryker Corp., Kalamazoo, MI).[@CIT0006] The Ahmed Glaucoma Valve model M4 plate surface area is 191 mm^2^ (revised surface area after the initial release of the implant, personal communication, New World Medical Inc., Rancho Cucamonga, CA), which is approximately the same surface area as the standard silicone-plate model FP7 (184 mm^2^). The theoretical surface area of the model M4 is higher because of the porous nature of the material. The average pore size is greater than 100 μm and pore volume is in the 50% range, with pore interconnections that allow the potential for tissue ingrowth. The M4 model plate was developed to allow tissue integration, which could increase surface area for absorption of aqueous and reduce encapsulation of the device.

In animal models, the Ahmed Glaucoma Valve with a surrounding porous membrane of expanded polytetrafluoroethylene (ePTFE) improved the hydraulic conductivity of the capsule around the implant.[@CIT0007],[@CIT0008] In pre-clinical animal studies, the Ahmed Glaucoma Valve model M4 was associated with thinner and more vascular capsules with reduced outflow resistance compared with the Ahmed Glaucoma Valve model S2.[@CIT0009] Retrospective clinical studies of the Ahmed Glaucoma Valve model M4 have shown variable results.[@CIT0010]--[@CIT0014] Although the model M4 porous-plate implant is approved by the Food and Drug Administration (FDA) for implantation in humans with intractable glaucoma, the production of the model M4 was voluntarily discontinued by the manufacturing company. Results regarding this implant are of interest for future development of glaucoma drainage implants. In this prospective, randomized, controlled study, we evaluated and compared the clinical outcomes after implantation of the Ahmed Glaucoma Valve model FP7 (silicone plate) and model M4 (porous polyethylene plate).

Patients and Methods {#S0002}
====================

This was a multicenter, prospective, randomized, controlled trial that enrolled patients from six sites, with one surgeon per site (P.A.N., V.P.C., L.A.A., I.I.K.A., S.R.S. and M.R.M.). The study was approved by the University of Virginia Institutional Review Board (IRB) and conformed to the requirements of the Declaration of Helsinki and the United States Health Insurance Portability and Privacy Act (HIPPA). The study was approved by the institutional review board for each site. All patients signed the informed consent before the screening. The trial was registered with [<http://clinicaltrials.gov>]{.ul} (identifier NCT01883856), with the study start date listed as the date of IRB approval at the sponsoring institution (University of Virginia) and the submission (registration) date listed after completion of IRB approval and site training completion of the other sites in this multicenter study.

Inclusion criteria were patients between ≥18 years and ≤80 years of age who were diagnosed with intractable glaucoma which has not responded to conventional medical and surgical therapy, mean elevated intraocular pressure of \>21 mmHg in two consecutive measurements using Goldmann applanation tonometry as baseline pressure, candidates for glaucoma drainage device surgery, and signed informed consent. Exclusion criteria precluded patients diagnosed with secondary glaucoma from silicone oil tamponade, prior drainage implant surgery, and history of cyclophotocoagulation. Pregnant and imprisoned patients were also excluded.

Baseline data and examinations collected were demographic information, glaucoma diagnosis, medical and ocular history, systemic medications, ocular medications, manifest refraction, Snellen visual acuity, mean intraocular pressure of two consecutive measurements by Goldmann applanation tonometry, slit-lamp examination, gonioscopy, fundus exam, 30--2 or 24--2 SITA Standard Humphrey Visual Field, and negative urine or serum pregnancy test for women of child-bearing potential. If both eyes of one patient qualified, the study eye was identified as the eye that had the highest baseline intraocular pressure or worse baseline visual acuity. Surgery was scheduled within 60 days of screening date. The patients were randomized 1:1 between the M4 and FP7 groups, with a computer-generated randomization scheme using varying block sizes of 2 to 4. The subject surgical intervention arm assignment was placed in a sealed envelope, securely delivered to sites, and opened by the site study staff in the surgical admission suite immediately before administering anesthesia to the patient. Post-randomization, the assigned surgical intervention arm was unmasked to both patient and surgeon.

Implantation of both models followed the guidelines as described previously.[@CIT0006],[@CIT0015] After adequate anesthesia, a fornix-based incision was made through the conjunctiva and Tenon's capsule. A pocket was formed in the quadrant between the rectus muscles by blunt dissection of Tenon's capsule from the episclera. The implant was examined and primed by injecting a balanced salt solution through the drainage tube and valve using a cannula. The primed implant was inserted into the pocket between the rectus muscles and sutured to the sclera. The leading edge was measured at approximately 8 mm from the limbus. The drainage tube was trimmed and inserted through a 23-gauge needle track into the anterior chamber at the limbus. The drainage tube was covered with donor sclera, cornea, or pericardium. The conjunctiva was closed. Minor variations of the surgical technique were at the discretion of the surgeon.

Postoperatively, patients were treated with topical corticosteroids and antibiotics, tapered over approximately six weeks. Scheduled follow-up visits were at 1 day, 1 month, 3 months, 6 months, 9 months, and 12 months postoperatively. Unscheduled visits were made according to the assessment of the surgeon. Data collected in the postoperative visits were visual acuity, intraocular pressure, slit lamp exam, gonioscopy (at 3, 6, 9, and 12 months only), fundus exam, adverse events and complications, and systemic and ocular medications. Glaucoma medication was added as necessary to achieve target intraocular pressure.

Surgical success was defined as 5 mmHg ≤ intraocular pressure ≤21 mmHg (with or without glaucoma medications), with no loss of light perception and no additional glaucoma procedures. An additional analysis of success based on percent lowering of intraocular pressure was performed, with success defined as 30% lowering of intraocular pressure from baseline (with or without medications), without loss of light perception and without additional glaucoma procedures. Bleb needling was not considered as an additional glaucoma procedure. Hypertensive phase was defined as intraocular pressure more than 21 mmHg during the first three months postoperatively. Primary endpoints of the study were the mean intraocular pressure and surgical success of the M4 group compared with the FP7 group at 12 months postoperatively. Secondary endpoints were comparisons of the mean glaucoma medications and complications in the M4 and FP7 groups.

The sample size was calculated with a power of 80% to detect a 1.5 mmHg in intraocular pressure with a standard deviation of 3 mmHg. Demographic and pre-operative data were compared with Chi-square test for homogeneity or Fisher's exact test, and independent-samples *t*-test or Mann Whitney U. Statistical significance of the differences of mean intraocular pressure and mean number of medications were determined using independent *t*-test. Kaplan-Meier survival analysis and log-rank test (Mantel-Cox) were performed to compare the cumulative probability of survival between the two groups. Proportions were compared using the comparison of proportions test (z test). Statistical analyses were done using SPSS version 25 (SPSS Inc., Chicago, IL).

Data sharing statement: deidentified participant data and the study protocol may be requested from the corresponding author up to 36 months following article publication. Proposals for use of deidentified data require approval by both an independent review committee at the University of Virginia and the University of Virginia IRB.

Results {#S0003}
=======

A total of 52 eyes from 52 patients were enrolled in the study, including 26 treated with the model M4 and 26 treated with the model FP7 Ahmed Glaucoma Valve. The demographic and preoperative data ([Table 1](#T0001){ref-type="table"}) showed no significant difference in population distribution with respect to surgical eye laterality, gender, age, ethnicity, lens status, glaucoma diagnosis and previous glaucoma surgery (*P*\>0.05). Eight patients were screen failures due to failure to meet inclusion and exclusion criteria. The number of patients analyzed was 52 at day 1, 48 at month 6, and 41 at month 12, due to removal of failures.Table 1Demographic and Preoperative Data for Patients Treated with the Porous Plate (Model M4) and Silicone Plate (Model FP7) Ahmed Glaucoma ValvesPorous Plate (Model M4) n=26Silicone Plate (Model FP7) n=26*P* valueEyes, right/left \[n\]17/910/160.052Age, years \[mean ± SD\]67.0 ± 10.167.7 ± 11.20.700Gender \[n (%)\]0.158 Female8 (30.8%)13 (50.0%) Male18 (69.2%)13 (50.0%)Ethnicity \[n (%)\]0.469 African9 (34.6%)8 (30.8%) Asian02 (7.7%) Caucasian14 (53.8%)14 (53.8%) Hispanic3 (11.5%)1 (3.8%) Mixed race01 (3.8%)Lens Status \[n (%)\]0.441 Phakic9 (34.6%)7 (26.9%) Pseudophakic17 (65.4%)17 (65.4%) Aphakic02 (7.7%)Glaucoma diagnosis \[n (%)\]0.384 Primary open-angle glaucoma14 (53.8%)15 (57.7%) Neovascular glaucoma6 (23.1%)5 (19.2%) Inflammatory (uveitic) glaucoma5 (19.2%)2 (7.7%) Combined mechanism glaucoma02 (7.7%) Congenital glaucoma01 (3.8%) Aphakic glaucoma01 (3.8%) Pseudoexfoliation glaucoma1 (3.8%)0Previous Glaucoma Surgery \[n (%)\]0.938 None17 (65.4%)15 (57.7%) Trabeculectomy (± EX-PRESS)8 (30.8%)8 (30.8%) Phaco-PCIOL and trabeculectomy1 (3.8%)1 (3.8%) EX-PRESS with iStent01 (3.8%) Triple procedure01 (3.8%)[^1]

Intraoperatively, tube placement was in the anterior chamber in 25 (96.2%) and 24 (92.3%), in the sulcus in 1 (3.8%) and 1 (3.8%), and in the pars plana in 0 (0%) and 1 (3.8%) in eyes treated with the model M4 and model FP7 plates, respectively (P = 1.0). The patch graft material used to cover the tube was cornea in 10 (38.5%) and 8 (30.8%), sclera in 10 (38.5%) and 11 (42.3%), pericardium in 4 (15.4%) and 5 (19.2%), and none (scleral tunnel) in 2 (7.7%) and 2 (7.7%) in eyes treated with the model M4 and model FP7 plates, respectively (P = 0.948).

[Figure 1](#F0001){ref-type="fig"} shows the mean intraocular pressure at all time points for both groups. Preoperative mean intraocular pressure was similar at 33.79 ± 10.5 mmHg and 29.91 ± 6.6 mmHg for the M4 and FP7 groups, respectively (*p* = 0.118). Both the M4 and FP7 groups had significant reductions in mean intraocular pressure at all time points during the study (P \> 0.05 for all time points), including 12 months postoperatively (P \< 0.0001 for both the M4 and FP7 groups). Although the intraocular pressure was lower during the early postoperative period and higher from months 3 to 12, the differences in mean intraocular pressure between groups were not statistically significant at any time point. A hypertensive phase occurred in 15 (57.7%) and 13 (50.0%) of the M4 group and the FP7 group, respectively (P = 0.578, [Table 2](#T0002){ref-type="table"}).Table 2Comparison of Efficacy and Complications in Patients Treated with the Porous Plate (Model M4) and Silicone Plate (Model FP7) Ahmed Glaucoma ValvesPorous Plate (Model M4) n = 26Silicone Plate (Model FP7) N = 26P value**Intraocular pressure \[mmHg; mean ± SD\]**Preoperative33.79 ± 10.5429.91 ± 6.550.118Postoperative month 1217.94 ± 10.9513.60 ± 4.690.141**Glaucoma medications \[mean ± SD\]**Preoperative3.31 ± 1.293.12 ± 1.340.600Postoperative month 121.89 ± 1.541.64 ± 1.400.605Hypertensive phase \[n (%)\]15 (57.7%)13 (50.0%)0.578Surgical success at 12 months \[n (%)\]14 (53.8%)23 (88.5%)0.005**Complications \[n (%)\]**Flat anterior chamber2 (7.7%)2 (7.7%)1.000Hypotony3 (11.5%)3 (11.5%)1.000Corneal edema1 (3.8%)1 (3.8%)1.000Tube occlusion1 (3.8%)2 (7.7%)1.000Tube repositioning01 (3.8%)1.000Wound leak1 (3.8%)01.000Choroidal effusion1 (3.8%)4 (15.4%)0.350Exposed plate/tube1 (3.8%)3 (11.5%)0.610Diplopia1 (3.8%)2 (7.7%)1.000Hemorrhagic choroidal detachment1 (3.8%)01.000Loss of vision \>than 2 Snellen lines3 (11.5%)4 (15.4%)1.000 Figure 1Mean intraocular pressure after M4 and FP7 Ahmed Glaucoma Valve implantation. The intraocular pressure was significantly reduced in both groups compared with baseline (P \< 0.05 at all time points). Comparisons of the individual time points showed no significant differences.**Abbreviations:** Pre, before surgery; D, day(s); M, month(s).

The mean number of medications was reduced in both the M4 group and the FP7 group at all time points after surgery (P \< 0.05). At 12 months after surgery, the mean number of medications was significantly lower in both groups (P = 0.009 in the M4 group and P \< 0.0001 in the FP7 group). As shown in [Figure 2](#F0002){ref-type="fig"}, the reduction of mean number of medications was similar in both groups at all time points. There was no statistically significant difference in the mean number of glaucoma medications between the two groups at any time points.Figure 2Number of glaucoma medications at baseline and postoperatively after M4 and FP7 Ahmed Glaucoma Valve implantation. The number of medications was significantly reduced in both groups compared with baseline (P \< 0.05 at all time points). There were no significant differences at any time point in comparisons between the two groups.**Abbreviations:** Pre, before surgery; D, day(s); M, month(s).

The cumulative probability of success ([Figure 3](#F0003){ref-type="fig"}) was significantly lower after implantation of the model M4 compared with the Model FP7 Ahmed Glaucoma Valve (P = 0.005, log-rank test). In this analysis, success was defined as 5 mmHg ≤ intraocular pressure ≤ 21 mmHg (with or without glaucoma medications), with no loss of light perception and no additional glaucoma procedures. The reasons for failure were intraocular pressure \> 21 mmHg in 6 (23.1%) and 1 (3.8%), intraocular pressure \< 5 mmHg in 2 (7.7%) and 0 (0%), additional glaucoma surgery in 3 (11.5%) and 2 (7.7%), and loss of light perception vision in 1 (3.8%) and 0 (0%) after implantation of the model M4 and model FP7 Ahmed Glaucoma Valve, respectively. The majority of the failures in the model M4 group were due to intraocular pressure \>21 mmHg. Glaucoma diagnosis of failures included primary open-angle glaucoma, neovascular glaucoma, uveitic glaucoma, and pseudoexfoliation glaucoma, which showed no significant differences between the model M4 and the FP7 groups (P = 1.00). Prior surgery in failures included trabeculectomy and cataract surgery, which showed no significant differences between groups (P = 0.604).Figure 3Kaplan--Meier curve cumulative probability of success in patients treated with model M4 and model FP7 Ahmed Glaucoma Valve implantation. Success was defined as 5 mmHg ≤intraocular pressure ≤21 mmHg (with or without medications), without loss of light perception and without additional glaucoma procedures. The success of eyes after model FP7 was significantly higher compared with model M4 implantation (P = 0.005).

The baseline intraocular pressure was not statistically significantly different comparing the M4 and FP7 groups (33.8 ± 10.5 mmHg and 29.9 ± 6.6 mmHg, respectively, P = 0.118). We evaluated the two groups for surgical success using an alternative definition for success, based on percent reduction of intraocular pressure from baseline. In this analysis, success was defined as 30% lowering of intraocular pressure from baseline (with or without medications), without loss of light perception and without additional glaucoma procedures ([Figure 4](#F0004){ref-type="fig"}). Kaplan--Meier curve cumulative probability of success was performed in patients treated with model M4 and model FP7 Ahmed Glaucoma Valve implantation. Using this definition of success, the surgical success of treatment with model FP7 was significantly higher compared with model M4 implantation (P = 0.014), which was similar to the finding using the definition of success using 5 mmHg ≤ intraocular pressure ≤21 mmHg (with or without glaucoma medications), with no loss of light perception and no additional glaucoma procedures.Figure 4Kaplan--Meier curve cumulative probability of success in patients treated with model M4 and model FP7 Ahmed Glaucoma Valve implantation. In this analysis, success was defined as 30% lowering of intraocular pressure from baseline (with or without medications), without loss of light perception and without additional glaucoma procedures. The success of eyes after model FP7 was significantly higher compared with model M4 implantation (P = 0.014).

As shown in [Table 2](#T0002){ref-type="table"}, there were no significant differences of postoperative complications in the Ahmed Glaucoma Valve model M4 and FP7 groups. Four patients developed shallow to flat anterior chambers that required reformation of the anterior chamber on postoperative day 7. One patient from the FP7 group with flat anterior chamber and lens-cornea touch developed lens opacification and underwent cataract extraction 8 months after Ahmed Glaucoma Valve implantation. Four patients developed exposed tube or plate and were treated with conjunctivoplasty and patch graft. A patient from the M4 group developed hemorrhagic choroidal detachment on postoperative day 7, and was treated with drainage of choroidals and pars plana vitrectomy one month after Ahmed Glaucoma Valve implantation, with recovery of preoperative vision by 6 months. The most common complication for both groups was loss of more than 2 Snellen lines of vision that was observed in 3 patients from the M4 group and 4 patients from the FP7 group.

Discussion {#S0004}
==========

This study compared the efficacy and safety of the porous polyethylene model M4 with the silicone model FP7 Ahmed Glaucoma Valves. In experimental studies, different glaucoma drainage implant plate materials may influence capsule formation and intraocular pressure control after glaucoma drainage implants.[@CIT0016],[@CIT0017] In clinical studies, different glaucoma drainage implant plate materials have been associated with significant differences of mean intraocular pressure in some[@CIT0005],[@CIT0018],[@CIT0019] but not all[@CIT0020],[@CIT0021] studies. In this randomized, prospective clinical trial, we compared the clinical outcomes after implantation of the porous polyethylene plate (model M4) with the silicone plate (model FP7) Ahmed Glaucoma Valves. We found differences in surgical success after Ahmed Glaucoma Valve implantation, with significantly lower success in the porous plate (M4) group compared with the silicone plate (FP7) group, with the majority of failures in the M4 group due to intraocular pressure \>21 mmHg.

In our study, we found differences in surgical success using two Ahmed Glaucoma Valve plates that differed in the materials used for their construction. Our results found significantly lower surgical success after implantation of the porous plate device compared with the silicone plate Ahmed Glaucoma Valve. Nine of twelve failures (75%) in the porous plate (model M4) group occurred due to intraocular pressure \>21 or additional glaucoma surgery required for increased intraocular pressure. We also found a trend towards increased intraocular pressure after the early postoperative period in the model M4 group compared with the model FP7 group. Our surgical failures showed no significant differences in glaucoma diagnosis or previous surgical history. A previous retrospective comparative study showed a trends toward increasing intraocular pressure and increasing failure rate after implantation of model M4 (porous plate), S2 (polypropylene), and FP7 (silicone), which were not statistically significantly different.[@CIT0010] Another retrospective non-comparative study showed a trend toward higher intraocular pressure after model M4 compared with model S2 implantation, but a survival analysis of surgical success was not performed.[@CIT0013] In previous non-comparative retrospective studies of the model M4 implant, the relatively high failure rates were consistent with those found in our study.[@CIT0012],[@CIT0014]

While we did not directly measure the capsule around the plate, the hypertensive phase and surgical success analyses provided clinical outcomes related to encapsulation around the plate. In previous retrospective studies, mitigated or no hypertensive phase was observed after model M4 Ahmed Glaucoma Valve implantation.[@CIT0010],[@CIT0014] Different variables may influence fibrous capsule formation and the hypertensive phase after glaucoma drainage implant surgery, including hydrostatic pressure and chemical mediators in the aqueous humor that may influence the fibrotic response.[@CIT0022],[@CIT0023] Aqueous suppression during the early postoperative period may reduce the hypertensive phase after Ahmed Glaucoma Valve implantation.[@CIT0024] In our randomized, prospective comparative study, hypertensive phase was not significantly different after implantation of the porous plate (model M4) or the silicone plate (model FP7) Ahmed Glaucoma Valves.

Integration of fibrovascular tissue into the porous plate could lead to differences in bleb morphology and clinical outcome measures. Differences in bleb morphology have been observed after implantation of the model M4 Ahmed Glaucoma Valve, with a low profile bleb presumably due to less aqueous in the cyst around the plate.[@CIT0010],[@CIT0012] Direct examination of the capsule during surgical explantation of 4 model M4 Ahmed glaucoma valves has been described,[@CIT0011] indicating that integration of fibrovascular tissue does occur. Variables that may influence tissue integration in the porous polyethylene plate are poorly understood, but may include time after surgery, pore size of the material, increased capsule-plate contact with aqueous suppression or flow restriction, and other variables. Cases of exposure of the model M4 posterior tube and the anterior corner of the plate have been described.[@CIT0011] In our study, we did not observe any significant differences in complications after model M4 and model FP7 Ahmed Glaucoma Valve implantation.

The failure rate may have been higher in the M4 group compared with the FP7 group for several reasons. Cvintal et al suggested that adhesions between the M4 plate and Tenon's capsule may prevent the formation of a diffuse filtration bleb, and inadequate tissue integration in the porous material may form a thick-walled bleb with higher outflow resistance and increased intraocular pressure.[@CIT0012] It is possible that less surface area was available for absorption of aqueous than anticipated with the porous material. Also, the plates are manufactured using polyethylene (model M4) and silicone (model FP7), which may differ in their biocompatibility, rigidity, inflammatory response, and other variables that may influence implant surgical outcomes. Use of differing materials has been associated with different clinical outcomes in previous studies of glaucoma drainage implants.[@CIT0005],[@CIT0016]--[@CIT0019]

A strength of our study is the randomized, prospective, comparative design. However, this study has limitations that may have influenced the results. Physicians were not masked to the treatment group during the postoperative period, the number of patients was relatively small, and the follow-up period was limited. Other differences between the plates, including the higher profile and the absence of fenestration holes in the M4 implant, could account for the differences we observed. Despite these limitations, we were able to demonstrate a significantly lower success rate after model M4 implantation, with the majority of failures in this group due to intraocular pressure \>21 mmHg and additional glaucoma surgery required for increased intraocular pressure.

Conclusions {#S0005}
===========

Intraocular pressure reduction was similar after implantation of the model M4 and model FP7 Ahmed Glaucoma Valves, with a trend toward increasing intraocular pressure after treatment with the model M4. The success rate was significantly lower after implantation of the porous polyethylene plate (model M4) compared with the silicone plate (model FP7). The majority of the failures in the model M4 group were due to increased intraocular pressure. Complications after surgery were similar in the two groups. Production of the model M4 was voluntarily discontinued by the manufacturer, although the device is approved by the Food and Drug Administration (FDA). Results from this study indicate that glaucoma drainage implant plate material may influence clinical outcomes.

Ahmed Glaucoma Devices were provided by New World Medical (Rancho Cucamonga, CA) for study implantation. There was no financial grant support provided for this investigator-initiated study. No company wrote or influenced the wording of the manuscript. Clinical trial registration ([<http://clinicaltrials.gov>]{.ul}) identifier NCT01883856, with the study start date listed as the date of IRB approval at the sponsoring institution (University of Virginia) and the submission (registration) date listed after completion of IRB approval and site training completion of the other sites in this multicenter study.
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[^1]: **Abbreviations:** Phaco-PCIOL, phacoemulsification and posterior chamber intraocular lens implantation; Triple procedure, phacoemulsification and posterior chamber intraocular lens implantation, trabeculectomy, and penetrating keratoplasty.
